The DOI matches its Crossref record; 51 of the 53 references it cites were found in a registry or an index.
Effects of long-term antidepressant treatment on oxidative status in major depressive disorder: A 24-week follow-up study
Abstract
Purpose Major depressive disorder (MDD) is a devastating disease that afflicts large populations and has also been accepted to be an independent risk factor for cardiovascular disease (CVD). Oxidative stress seems to play an essential role in the relationship of MDD and CVD. We aimed to determine the level of oxidative stress in patients with MDD and to investigate the effects of long-term antidepressant (AD) treatment on the oxidative-antioxidative system parameters and CVD risk factors.Method Fifty patients who fully met the fourth Diagnostic and Statistical Manual of Mental Disorders criteria for MDD and 44 healthy control subjects were included in the study. Control visits of the patients were repeated 6weeks, 12weeks and 24weeks after beginning of the AD treatment. Lipid profiles, oxidation and oxidizability of apolipoprotein B-containing lipoproteins (expressed as apo B-b-MDA and apo B-Δ-MDA, respectively), levels of plasma malondialdehyde (p-MDA), total antioxidative capacity (TAOC), antioxidant molecules and antioxidant enzyme activities including paraoxonase/arylesterase, red blood cell superoxide dismutase (RBC-SOD) and glutathione peroxidase were determined during 24-week of follow-up period.Results According to the results of the study, p-MDA, apo B-b-MDA and RBC-SOD activity were increased and arylesterase activity was decreased in MDD patients. Body mass index (BMI), vitamin A and total cholesterol levels in MDD patients increased after 24-weeks of AD treatment. RBC-SOD activity, TAOC, p-MDA and apo B-b-MDA levels were decreased; paraoxonase/arylesterase activities and apo B-Δ-MDA were increased at the end of 24th week.Conclusion Oxidative stress, demonstrated in MDD patients, was partly improved during 24weeks of AD treatment. Increase in paraoxonase/arylesterase activities and decrease in p-MDA and apo B-b-MDA levels after 24weeks seem to be beneficial for reduction of CVD risk in MDD patients. However increased BMI and apo B-Δ-MDA levels are negative cardiovascular effects of long-term AD treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, TAC was also found decreased after 24-week treatment with antidepressants”
From Preclinical and Clinical Evidence of Antioxidant Effects of Antidepressant Agents: Implications for the Pathophysiology of Major Depressive Disorder (2012) · cites this paper as [33]
In the citing paper
“Plasmatic MDA, serum oxidized LDL (OxLDL) levels, and erythrocyte SOD activity were increased in MDD patients before treatment”
From Preclinical and Clinical Evidence of Antioxidant Effects of Antidepressant Agents: Implications for the Pathophysiology of Major Depressive Disorder (2012) · cites this paper as [33]
In the citing paper
“After 24-weeks of treatment, MDA and SOD levels decreased.”
From Preclinical and Clinical Evidence of Antioxidant Effects of Antidepressant Agents: Implications for the Pathophysiology of Major Depressive Disorder (2012) · cites this paper as [33]
In the citing paper
“and MDA levels were positively correlated with the severity of MDD.”
From Preclinical and Clinical Evidence of Antioxidant Effects of Antidepressant Agents: Implications for the Pathophysiology of Major Depressive Disorder (2012) · cites this paper as [33]
In the citing paper
“Patients on venlafaxine were also compared with patients on SSRIs in the aspect of oxidative stress parameters in the follow-up period, but no significant differences were found [33].”
From Preclinical and Clinical Evidence of Antioxidant Effects of Antidepressant Agents: Implications for the Pathophysiology of Major Depressive Disorder (2012) · cites this paper as [33]
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,845
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2022) · doi:10.1176/appi.books.9780890425787 · Cited by 23,476
Free radicals and antioxidants in normal physiological functions and human disease
Valko, M., Leibfritz, D., Moncol, J., Cronin, M. T. D., Mazur, M., & Telser, J. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2006.07.001 · Cited by 14,269
[30] Microsomal lipid peroxidation
Buege, J. A., & Aust, S. D. (1978) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(78)52032-6 · Cited by 13,564
Tietz Textbook of Clinical Chemistry
(1999) · Archives of Pathology & Laboratory Medicine · doi:10.5858/123.7.646b · Cited by 2,518
The role of lipid peroxidation and antioxidants in oxidative modification of LDL
Esterbauer, H., Gebicki, J. M., Puhl, H., & Jürgens, G. (1992) · Free Radical Biology and Medicine · doi:10.1016/0891-5849(92)90181-f · Cited by 2,307
Maes, M., Galecki, P., Chang, Y. S., & Berk, M. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.05.004 · Cited by 1,140
Depression as a Risk Factor for Coronary Artery Disease: Evidence, Mechanisms, and Treatment
Lett, H. S., Blumenthal, J. A., Babyak, M. A., Sherwood, A., Strauman, T. J., Robins, C., & Newman, M. F. (2004) · Psychosomatic Medicine · doi:10.1097/01.psy.0000126207.43307.c0 · Cited by 847
The human serum paraoxonase/arylesterase polymorphism.
Eckerson, H. W., Wyte, C. M., & Du, B. N. L. (1983) · PubMed · Cited by 732
Flagged first, then by citations
2 of the 53 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- Akdemir, 1996, Validity-reliability and clinical use of Turkish version of Hamilton depression rating scale, Psikiyatri Psikol Psikofarmakol Derg, 4, 251
- Yazici, 1998, Hamilton Anxiety Rating Scale, Interrater reliability and validity study, Turk J Psychiatry, 9, 114
Cited by
Sorted by citations
Items 101–149 of 149
Relationship Between Obesity and Depression Considering the Inflammatory Theory
Oracz, A. J., Zwierz, M., Naumowicz, M., Suprunowicz, M., & Waszkiewicz, N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26114966 · Cited by 20
“These results have been echoed by other studies on lipid peroxidation in MDD and its modulation by antidepressant therapy, which have shown that MDA levels tend to decrease following effective treatment [197–199].”
Thiol/Disulfide Homeostasis in Bipolar and Unipolar Depression
Erzin, G., Özkaya, G., Topçuoğlu, C., Yüksel, R., Erel, Ö., Yurt, E., Göka, E., & Gülöksüz, S. (2020) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2020.18.3.395 · Cited by 10
Plant Adaptogens: Natural Medicaments for 21 st Century?
Özdemir, Z., Bildziukevich, U., Wimmerová, M., Macůrková, A., Lovecká, P., & Wimmer, Z. (2018) · ChemistrySelect · doi:10.1002/slct.201702682 · Cited by 17
Bai, Y., Liu, W., Zhang, F., Zheng, Y., Guo, Q., Hu, H., Hu, Y. F., Chen, H., Li, G., Tang, Y., et al. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.04.066 · Cited by 13
Çimen, B., Gumus, C. B., Çetin, İ., Özsoy, S., Aydin, M., & Çimen, L. (2015) · Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology · doi:10.5455/bcp.20150215102247 · Cited by 12
Biomarkers of Oxidative Stress in Major Depressive Disorder
Hamed, R. A., Elmalt, H. A., Salama, A., Abozaid, S. Y., & Ahmed, A. (2020) · Open Access Macedonian Journal of Medical Sciences · doi:10.3889/oamjms.2020.4144 · Cited by 12
“[33] who found that there was a positive correlation between the severity of depressive symptoms and SOD activity.”
BackgroundPolak-Szabela, A., Dziembowska, I., Bracha, M., Pedrycz, A., Kędziora–Kornatowska, K., & Kozakiewicz, M. (2021) · Clinical Interventions in Aging · doi:10.2147/cia.s310750 · Cited by 11
“The effectiveness of depression treatment can consist of inhibiting the activity of pro-inflammatory cytokines and oxidative stress, tilting the balance in favor of antioxidant mechanisms.(51,52) In the neuropsychological picture, people in the AD and AD+D groups revealed a decrease in the ability to create and speak…”
BackgroundOxidative Stress in Depression
Gałecki, P. (2014) · Springer eBooks · doi:10.1007/978-3-642-30018-9_190 · Cited by 11
Roman, W. A., Piato, Â., Conterato, G. M. M., Wildner, S. M., Marcon, M., Moreira, S., Santo, G. D., Mocelin, R., Emanuelli, T., & Santos, C. A. D. M. (2013) · Pharmacognosy Journal · doi:10.1016/j.phcgj.2013.05.003 · Cited by 11
Zimath, P. L., Dalmagro, A. P., da Silva, L. M., Malheiros, Â., & de Souza, M. M. (2021) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2021.109603 · Cited by 10
Ahmed, A. S., Mona, M. M., Elsisy, R. A., & Hantash, E. M. (2021) · Neurotoxicity Research · doi:10.1007/s12640-021-00433-y · Cited by 10
Expression of PON1, PON2, PON3 and MPO Genes in Patients with Depressive Disorders
Bliźniewska-Kowalska, K. M., Gałecki, P., Su, K., Halaris, A. E., Szemraj, J., & Gałecka, M. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11123321 · Cited by 9
Zhu, Y., Li, Y., Yu, Z., Chen, X., Lan, T., Wang, M., & Yu, S. Y. (2025) · Antioxidants · doi:10.3390/antiox14040410 · Cited by 10
Chen, Z., Liang, S., Bai, Y., Lin, J., Li, M., Mo, Z., Xie, S., Huang, S., & Long, J. (2022) · European Journal of Clinical Nutrition · doi:10.1038/s41430-022-01165-8 · Cited by 9
de Aquino, G. Â., de Sousa, C. N. S., Medeiros, I. D. S., de Almeida, J. C., Filho, F. M. S. C., Júnior, M. A. S., & Vasconcelos, S. M. M. (2021) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp-2021-0056 · Cited by 7
Kamrani, F., Kachouei, A. A., Fereydouni, N., Tanbakuchi, D., Esmaily, H., Moohebati, M., Mahaki, H., Rezaee, A., Darroudi, S., Ghayour‐Mobarhan, M., et al. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.08.172 · Cited by 8
Tayeb, A. E. K. A., Becquemont, L., El‐Asmar, K., Mahmoudi, K., Colle, R., Trabado, S., Gressier, F., Fève, B., Corruble, E., & Verstuyft, C. (2020) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13385 · Cited by 7
Advances and Challenges in Depression Marker Research
Jin, W., Chen, S., Li, D., Chen, Q., Zhu, M., Wang, M., Fu, X., & Lin, P. C. (2025) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s527897 · Cited by 7
“57,58 Abnormal lipid metabolism is also one of the important features of depression, and abnormal cholesterol levels have been observed in the serum of depressed patients.”
Gao, J., Liu, Y., Zhou, S., Liu, Q., Saateh, A., Altug, H., Wang, T., Guo, B., & Xu, J. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5c13180 · Cited by 5
Gupta, R., Ghosh, R., Bhatia, M. S., Tripathi, A., & Gupta, L. K. (2023) · Acta Neurobiologiae Experimentalis · doi:10.55782/ane-2023-006 · Cited by 6
Ensan, B., Hosseini, Z. S., Mirzaei, M., Hakim, H. G., Zafari, N., Jamialahmdi, T., & Sahebkar, A. (2024) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2024.2427617 · Cited by 5
“…support any significant association between plasma tc levels and depression, compared to the control group (Bilici et al., 2001; huang & chen, 2004; Kotan et al., 2011; liu et al., 2015; Onuegbu et al., 2010; sagud et between groups exerted no significant effect on tc levels (Wei et al., 2020). it…”
Vaghef‐Mehrabany, E., Izadi, A., & Ebrahimi‐Mameghani, M. (2021) · Health Promotion Perspectives · doi:10.34172/hpp.2021.62 · Cited by 5
Paraoxonase (PON1) L55M and Q192R polymorphisms in major depression and bipolar affective disorder
Yıldız, M., Çelıkel, F. Ç., Ateş, Ö., Taycan, S. E., Benli, İ., & Demir, O. (2017) · Archives of Clinical Psychiatry (São Paulo) · doi:10.1590/0101-60830000000123 · Cited by 5
Almulla, A. F., Thipakorn, Y., Algon, A. A. A., Tunvirachaisakul, C., Al‐Hakeim, H. K., & Maes, M. H. J. (2023) · medRxiv · doi:10.1101/2023.03.20.23287483 · Cited by 5
“, in a longitudinal study, found that antidepressant treatments significantly decrease plasma MDA and increase PON1 activities (Kotan et al., 2011).”
BackgroundThiol/Disulfide Homeostasis: A Potential New Peripheral Biomarker in Adolescent Depression
Öztürk, M., Özkan, Y., Sapmaz, Ş. Y., Erdal, S., Taneli, F., & Kandemır, H. (2024) · Psychiatry and Clinical Psychopharmacology · doi:10.5152/pcp.2024.23744 · Cited by 4
Malmberg, C., Hellquist, B. N., Sadanandan, S. A., Sandström, M., Wu, W., Björkblom, B., Melin, B. S., & Sjöberg, R. L. (2024) · American Journal of Epidemiology · doi:10.1093/aje/kwae100 · Cited by 4
Azimzadeh, K., Jafarpour, H., & Adldoost, S. (2017) · Pharmaceutical and Biomedical Research · doi:10.29252/pbr.3.3.17 · Cited by 4
“after 24 weeks of antidepressant medication (21).”
Cao, P., Xu, M., Ye, M., Yang, W., & Fang, M. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1539158 · Cited by 4
Paraoxonase (PON1) L55M and Q192R polymorphisms in major depression and bipolar affective disorder
Yıldız, M., Çelıkel, F. Ç., Ateş, Ö., Taycan, S. E., Benli, İ., & Demir, O. (2017) · Journal of Mood Disorders · doi:10.5455/jmood.20170304070525 · Cited by 2
THE ROLE OF OXIDATIVE STRESS IN THE ETIOPATHOGENESIS OF DEPRESSION
Komsiyska, D., & Petkov, Y. (2019) · Trakia Journal of Sciences · doi:10.15547/tjs.2019.01.013 · Cited by 2
“patients do not differ from healthy subjects with respect to the plasma levels of vitamins A, C and E (57).”
BackgroundUric Acid: A Biomarker and Pathogenic Factor of Affective Disorders and Neurodegenerative Diseases
Chu, T., Liu, G., Liu, J., Wu, Y., & Fang, W. (2024) · Current Pharmaceutical Design · doi:10.2174/0113816128333916241003180018 · Cited by 1
Sayed, M. M., Gaafary, M. M. E., Elsheikh, M. M. E., Hamed, S. S., Mohamed, R. M. A., & Mohamed, M. Y. (2025) · Middle East Current Psychiatry · doi:10.1186/s43045-025-00549-3 · Cited by 1
“Similar to our findings, several previous studies from various groups of patients have shown non-significant differences in serum albumin levels between patients and controls [8, 19, 38, 54].”
Xu, Z., Wang, J., Chang, T., Li, Y., Jia, H., & Zhang, X. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.121252 · Cited by 1
Melatonin: A versatile neuroprotective molecule in neurodegenerative diseases: A narrative review
Jazi, A. A., Yousefi, S., Reiter, R. J., Mojaveraghili, S. B., Amirkhanlou, S., Yekani, M., Farzanegan, S., Mir, S. M., & Memar, M. Y. (2026) · Tissue and Cell · doi:10.1016/j.tice.2026.103884 · Cited by 1
Gomes, A. D. A., & Eleutério, B. M. G. (2023) · Revista Ibero-Americana de Humanidades, Ciências e Educação · doi:10.51891/rease.v9i10.11788 · Cited by 1
Murukan, G., & Murugan, K. (2018) · International Journal of Pharma and Bio Sciences · doi:10.22376/ijpbs.2018.9.3.p38-46 · Cited by 1
Lühike ülevaade mõningatest antidepressantide kliinilist efektiivsust mõjustavatest teguritest
Pokk, P. (2014) · Ajakirjad. Journals by UT · doi:10.15157/ea.v0i0.11732
Oxidative stress and neuronal resilience – implications for the pathophysiology of bipolar disorder
Colpo, G. D., Fries, G. R., Stertz, L., & Kapczinski, F. P. (2016) · Cambridge University Press eBooks · doi:10.1017/cbo9781107477278.007
Oxidative Stress in Depression 103
Gaøecki, P. (2014)
Schoeman, J. C. (2015) · Boloka Institutional Repository (North-west University)
Li, Y., Yuan, Q., Yu, Y. T., Zhao, Z., & Guo, R. (2019) · Neuropsychiatry · doi:10.4172/neuropsychiatry.1000562
Elnovriza, D., Riyadi, H., Rimbawan, R., Damayanthi, E., & Winarto, A. (2020) · Journal of Nutritional Science and Vitaminology · doi:10.3177/jnsv.66.s36
δEPCD: the electrophysiologic coefficient of depressiveness
Khalil, R. B., & Khoury, R. E. (2021) · Biomarkers · doi:10.1080/1354750x.2021.1995497 · Cited by 1
Hussein, O., Izakson, L., & Zidan, J. (2021) · Research Square · doi:10.21203/rs.3.rs-1027124/v1
Arıcıoğlu, F., & Leonard, B. E. (2022) · Neuromethods · doi:10.1007/978-1-0716-2083-0_5
Decreased PON1 activity as a biological marker for depressive disorders: a narrative review
Levada, O. A., & Troian, O. (2025) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2025.100947
Ma, J., Wang, R., Chen, Y., Wang, Z., & Dong, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26566064
Ma, J., Wang, R., Chen, Y., Wang, Z., & Dong, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26566061
Gao, J., Kim, J., Ross, C. K., Sun, X., Fan, S., Liu, Y., Guo, B., & Xu, J. (2026) · ACS Sensors · doi:10.1021/acssensors.6c00495
Metadata
- Authors
- Kotan, V. O., Sarandol, E., Kirhan, E., Ozkaya, G., & Kirli, S.
- Corresponding author
- Kotan, Vahap Ozan
- ORCID
- Kotan, Vahap Ozan
- Venue
- Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Publisher
- Elsevier BV
- Published
- 2011-07
- Volume
- 35
- Issue
- 5
- Pages
- 1284-1290
- ISSN
- 0278-5846 (ISSN-L)
- OpenAlex
- W2016056242
- Cited by
- 149
- References
- 53
- Citations by year
- 2026: 3 · 2025: 9 · 2024: 9 · 2023: 8 · 2022: 6 · 2021: 11 · 2020: 16 · 2019: 9 · 2018: 5 · 2017: 16 · 2016: 11 · 2015: 13 · 2014: 11 · 2013: 11 · 2012: 9
- FWCI
- 6.85
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Progress in Neuro-Psychopharmacology and Biological Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Bursa Uludag University - AVESIS (submittedVersion)
- Topics
- Health Sciences › Medicine › Biochemistry (medical) › Antioxidant Activity and Oxidative Stress
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- major depressive disorder, antidepressant treatment, oxidative stress, malondialdehyde, apolipoprotein B, lipid peroxidation, superoxide dismutase, glutathione peroxidase, total antioxidant capacity, cardiovascular risk, body mass index, vitamin A, cholesterol
- MeSH terms
- Adult, Antidepressive Agents, Antioxidants, Apolipoproteins, Blood Cell Count, Carboxylic Ester Hydrolases, Cardiovascular Diseases, Major Depressive Disorder, Female, Follow-Up Studies, Hormones, Humans, Lipids, Liver Function Tests, Long-Term Care, Male, Malondialdehyde, Psychiatric Status Rating Scales, Risk Factors, Superoxide Dismutase, Body Mass Index, Oxidative Stress, Aryldialkylphosphatase, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
